Tissue Regenix Group PLC Issue of Equity and Total Voting Rights (5685B)

TIDMTRX

RNS Number : 5685B

Tissue Regenix Group PLC

07 June 2019

Tissue Regenix Group plc

Issue of Equity and Total Voting Rights

Leeds, 07 June 2019 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Company"), the regenerative medical devices company, announces that it has today issued and allotted 240,499 ordinary shares of 0.5p each in the Company, following an exercise of options which were granted in respect of the 2015 and 2018 DAB awards.

The 240,499 new ordinary shares will rank pari passu with the existing ordinary shares and application will shortly be made for these new ordinary shares to be admitted to trading on AIM. It is expected that Admission will occur at 8:00a.m. on 13 June 2019.

Total Voting Rights

Following the issue of the 240,499 new ordinary shares, the Company will have a total of 1,171,971,322 ordinary shares of 0.5p each in issue. The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For more Information:

 
 Tissue Regenix Group plc                       Tel: [phone] / 
  Caitlin Pearson Head of Communications         07920272 441 
---------------------------------------------  --------------------- 
 
 Stifel Nicolaus Europe Limited (Nominated      Tel: [phone] 
  Adviser and Broker) 
  Jonathan Senior / Alex Price / Ben Maddison 
---------------------------------------------  --------------------- 
 
 FTI Consulting                                 Tel: [phone] 
  Brett Pollard / Victoria Foster Mitchell 
  / Mary Whittow 
=============================================  ===================== 
 

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL(R) ') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies(R) , a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

IOEFRMJTMBIMBJL

(END) Dow Jones Newswires

June 07, 2019 09:55 ET (13:55 GMT)